Insider Trading Activity For AbbVie Inc. (NYSE:ABBV)
Richard A Gonzalez , CEO of AbbVie Inc. (NYSE:ABBV) reportedly Sold 65,861 shares of the company’s stock at an average price of 71 for a total transaction amount of $4,676,131.00 SEC Form
Insider Trading History For AbbVie Inc. (NYSE:ABBV)
On 2/4/2013 Frederick H Waddell, Director, bought 2,000 with an average share price of $37.05 per share and the total transaction amounting to $74,100.00.View SEC Filing
On 3/11/2013 Edward J Rapp, Director, bought 2,500 with an average share price of $37.67 per share and the total transaction amounting to $94,175.00.View SEC Filing
On 8/12/2013 Azita Saleki-Gerhardt, SVP, sold 8,851 with an average share price of $44.91 per share and the total transaction amounting to $397,498.41.View SEC Filing
On 8/19/2013 Azita Saleki-Gerhardt, SVP, sold 1,270 with an average share price of $43.01 per share and the total transaction amounting to $54,622.70.View SEC Filing
On 9/17/2013 Azita Saleki-Gerhardt, SVP, sold 10,473 with an average share price of $45.84 per share and the total transaction amounting to $480,082.32.View SEC Filing
On 3/3/2014 William Chase, CFO, sold 3,948 with an average share price of $50.22 per share and the total transaction amounting to $198,268.56.View SEC Filing
On 3/3/2014 Carlos Alban, EVP, sold 2,882 with an average share price of $50.09 per share and the total transaction amounting to $144,359.38.View SEC Filing
Analyst Ratings For AbbVie Inc. (NYSE:ABBV)
These are 7 Hold Ratings, 6 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for AbbVie Inc. (NYSE:ABBV) is Buy (Score: 2.57) with a consensus target price of $75.54 , a potential (6.41% upside)
Analyst Ratings History For AbbVie Inc. (NYSE:ABBV)
- On 12/18/2015 Atlantic Securities Initiated Coverage of rating Neutral with a price target of $59.00
- On 6/8/2016 Morgan Stanley Downgraded rating Overweight to Equal Weight with a price target of $73.00 to $65.00
- On 8/2/2016 Barclays PLC Reiterated Rating Equal Weight with a price target of $68.00
- On 8/8/2016 Argus Reiterated Rating Buy with a price target of $85.00
- On 9/1/2016 Raymond James Financial, Inc. Initiated Coverage of rating Outperform with a price target of $82.00
- On 9/8/2016 J P Morgan Chase & Co Downgraded rating Overweight to Neutral with a price target of $75.00 to $73.00
- On 11/28/2016 Citigroup Inc. Downgraded rating Buy to Neutral with a price target of $60.00
Dividend Information For AbbVie Inc. (NYSE:ABBV)
AbbVie Inc. (NYSE:ABBV) pays an annual dividend of Community Ranking: with a yield of 3.61% and an average dividend growth of 12.50% (3 Year Average).
Dividend History For AbbVie Inc. (NYSE:ABBV)
On 1/4/2013 AbbVie Inc. announced a quarterly dividend of $0.40 with an ex dividend date of which will be payable on 2/15/2013.
On 1/7/2013 AbbVie Inc. announced a special dividend of $0.40 with an ex dividend date of 1/11/2013 which will be payable on 2/15/2013.
On 2/15/2013 AbbVie Inc. announced a quarterly dividend of $0.40 4.19% with an ex dividend date of 4/11/2013 which will be payable on 5/15/2013.
On 6/20/2013 AbbVie Inc. announced a quarterly dividend of $0.40 3.75% with an ex dividend date of 7/11/2013 which will be payable on 8/15/2013.
On 9/19/2013 AbbVie Inc. announced a quarterly dividend of $0.40 3.34% with an ex dividend date of 10/10/2013 which will be payable on 11/15/2013.
On 12/12/2013 AbbVie Inc. announced a quarterly dividend of $0.40 3.06% with an ex dividend date of 1/13/2014 which will be payable on 2/14/2014.
On 2/20/2014 AbbVie Inc. announced a quarterly dividend of $0.42 3.29% with an ex dividend date of 4/11/2014 which will be payable on 5/15/2014.
Recent Trading Activity for AbbVie Inc. (NYSE:ABBV)
Shares of AbbVie Inc. closed the previous trading session at 70.99 0.00 0.00% with 4,731,596 shares trading hands.